title: Cancer risk assessment for 1,3-butadiene: dose-response modeling from an epidemiological perspective.
abstract: The dose-response assessment of the association between 1,3-butadiene (BD) and leukemia mortality among workers in the North American synthetic rubber industry is explored. Analyses are based on the most recent University of Alabama at Birmingham epidemiological study and exposure estimation. The U.S. EPA Science Advisory Board recommendations of using the most recent data and giving consideration to peak exposures to BD have been followed. If cumulative BD ppm-years is to be used as the predictor of the leukemia rate ratio, then the performance of that predictor is statistically significantly improved if the slope in the predictor is estimated with age and the cumulative number of BD peaks (where a BD peak is any exposure, regardless of duration, to a BD concentration above 100 ppm) added as categorical covariates. After age and the cumulative number of BD peaks are incorporated as categorical covariates in the Poisson regression model, the estimated concentration (EC(001)) corresponding to an excess risk of 0.001 as a result of continuous environmental exposure is 11.2 ppm; however, the estimated slope for BD cumulative ppm-years in the linear rate ratio for leukemia used to derive this EC(001) is not statistically significantly different from zero. Sensitivity analyses using alternative models indicate either essentially no risk or estimated EC(001) values of 9 and 77 ppm. Analyses suggesting the absence of a statistically significant low-dose risk versus cumulative BD ppm-years are presented. Sensitivity analyses of other malignant neoplasms of lymphatic and hematopoietic tissue (specifically, lymphoid and myeloid neoplasms) resulted in conclusions about the dose-response modeling methodology that were supportive of the methodology used for leukemia.
authors.affiliation: Sielken and Associates Consulting, Inc., 3833 Texas Avenue, Suite 230, Bryan, TX 77802, USA. SielkenAssoc@aol.com
authors.forename: Robert L
authors.initials: RL
authors.lastname: Sielken
authors.forename: Ciriaco
authors.initials: C
authors.lastname: Valdez-Flores
authors.forename: Michael L
authors.initials: ML
authors.lastname: Gargas
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Kirman
authors.forename: M Jane
authors.initials: MJ
authors.lastname: Teta
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Delzell
mesh_terms: D000375:Aging; D002070:Butadienes / Q000008:administration & dosage* / Q000009:adverse effects*; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007945:Leukemia, Lymphoid / Q000453:epidemiology / Q000401:mortality; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000401:mortality; D016013:Likelihood Functions; D008954:Models, Biological; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D016273:Occupational Exposure; D018570:Risk Assessment; D014481:United States / Q000453:epidemiology
chemical_list: D002070:Butadienes; D002273:Carcinogens